CoRegen

CoRegen is pioneering a new cancer treatment method by targeting the SRC-3 gene in regulatory T (Treg) cells, a form of adoptive cell therapy (ACT), enabling the immune system to recognize and eliminate solid tumors. Research from the O'Malley Lab at Baylor College of Medicine shows that preclinical models indicate genetically modified Tregs alter their behavior, allowing them to penetrate tumors, release cytokines, and recruit immune cells to eradicate tumors.